Navigating Advancements in Diagnosis & Treatment of Axial Spondyloarthritis

To participate in this activity, please:

More than 80% of the population has significant back pain at some point in their life, with 30% of adults in the United States stating they have chronic low back pain at any given time; 5% of whom have inflammatory back pain. Axial spondyloarthritis (axSpA) affects almost 1.5% of patients with inflammatory back pain; however, the majority of individuals suffering with back pain are not being treated by a rheumatologist, which only exacerbates the challenge to diagnose those with axSpA.

In this subway themed activity, Dr. Leonard Calabrese discusses both radiographic and nonradiographic ankylosing spondylitis in detail, differentiating their diagnostic properties and how to properly treat and manage patients with this inflammatory disease that affects daily function and quality of life. Dr. Calabrese emphasizes appropriate testing and imaging with use of ASAS guidelines to provide an accurate diagnosis, while sharing case examples through disease progression and treatment selection.

Course Credit:

1.00 AMA PRA Category 1 CreditTM


Opens: 2020-08-31
Closes: 2021-08-30

Target Audience:

This activity is intended for rheumatologists, primary care physicians, nurse practitioners, physician assistants and other healthcare providers who diagnose and manage patients with axial spondyloarthritis.

This activity is supported by an independent educational grant from Eli Lilly.
  • Leonard Calabrese, DO

    Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Director, RJ Fasenmyer Center for Clinical Immunology
    Cleveland Clinic
    Cleveland, Ohio

Learning Objectives

  • Diagnose ankylosing spondylitis (AS) using ASAS guidelines
  • Diagnose non-radiographic axial spondyloarthritis (nr-axSpA) using ASAS guidelines
  • Utilize validated tools to assess AxSpA disease burden and response to treatment
  • Summarize the safety and efficacy of biologic treatments for AxSpA
  • Utilize a treat-to-target approach with individualized evidence-based therapy to reduce symptom burden and, when possible, achieve disease remission/low disease activity

Faculty Disclosures

Leonard Calabrese, DO

Consultant: AbbVie, Amgen, BMS, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Horizon, Jansen, Kiniksa, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB

Speakers Bureau: AbbVie, BMS, Genentech, Novartis, Regeneron, Sanofi-Genzyme

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Victoria Anderson (Medical Writer)
  • Individual stockholder
    • Abbott 
    • AbbVie

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.